Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 9:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Healthy Infants Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants

NCT04126213
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MAT 60 µg, RSV MAT 120 µg, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
534 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
13
States / cities
Phoenix, Arizona • Huntington Park, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2021 · Synced Jun 26, 2026, 9:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

BabyQ's: Randomized Controlled Trial of Health Messaging in Pregnancy and Infancy

NCT04238585
View directory record Official record
Conditions
Pregnancy Related, Infant Development
Interventions
Mobile messaging
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
291 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Jun 26, 2026, 9:25 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants

NCT02096263
View directory record Official record
Conditions
Poliomyelitis, Diphtheria, Haemophilus Influenzae Type b, Tetanus, Acellular Pertussis, Hepatitis B
Interventions
Infanrix hexa, Pediarix, ActHIB, Pentacel, Engerix-B, Infanrix, Hiberix, Prevnar13, Rotarix
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
585 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
43
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Anaheim, California + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Jun 26, 2026, 9:25 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Structure and Development in Pre-Term and Full-Term Infants

NCT00679471
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
Christiana Care Health Services
Other
Eligibility
Up to 30 Months
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
2
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Jun 26, 2026, 9:25 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Tolerance and Development of Healthy, Term Infants

NCT00465764
View directory record Official record
Conditions
Healthy
Interventions
Alternate protein infant formula, Standard infant formula
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
1 Day to 8 Days
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Lincoln, Nebraska • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2009 · Synced Jun 26, 2026, 9:25 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Comparative Single-Dose Pharmacokinetic (PK) and Safety Study of Azilsartan Medoxomil in Children With Hypertension and in Healthy Adults

NCT01078376
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan medoxomil (TAK-491)
Drug
Lead sponsor
Takeda
Industry
Eligibility
1 Year to 45 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
4
States / cities
Little Rock, Arkansas • Atlanta, Georgia • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Jun 26, 2026, 9:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants

NCT02290340
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
Placebo, MEDI8897 10 mg, MEDI8897 25 mg, MEDI8897 50 mg
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
Up to 12 Months
Enrollment
151 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
7
States / cities
Anaheim, California • Ontario, California • Syracuse, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Jun 26, 2026, 9:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Adhesive Tape Trauma Evaluation of Two Gentle Tapes

NCT01354106
View directory record Official record
Conditions
Adhesive Tape Trauma
Interventions
Skin Trauma
Device
Lead sponsor
Solventum US LLC
Industry
Eligibility
6 Months to 4 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Jun 26, 2026, 9:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Microneedle Patch Study in Healthy Infants/Young Children

NCT03207763
View directory record Official record
Conditions
Vaccination, Skin Absorption
Interventions
Microneedle Formulation 1, Microneedle Formulation 2
Device
Lead sponsor
Emory University
Other
Eligibility
6 Weeks to 24 Months
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Jun 26, 2026, 9:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Pharmacokinetics and Safety of Co-administered Oral Galicaftor, Navocaftor, and ABBV-576 in Healthy Adults for the Treatment of Cystic Fibrosis

NCT05530278
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Galicaftor, ABBV-576, Navocaftor, Midazolam
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
4
States / cities
Anaheim, California • Miami, Florida • Las Vegas, Nevada + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Jun 26, 2026, 9:25 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Healthy Term Infants Fed Milk-Based Formulas

NCT01617889
View directory record Official record
Conditions
Healthy Term Infant
Interventions
Experimental powdered milk-based infant formula with an alternate fat blend, A powdered milk-based infant formula, standard fat blend
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
53 Days to 115 Days
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 14, 2013 · Synced Jun 26, 2026, 9:25 AM EDT
Completed No phase listed Observational

Segmental Bronchoalveolar Lavage

NCT00001618
View directory record Official record
Conditions
Asthma, Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 65 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Jun 26, 2026, 9:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of Lactobacillus Reuteri (L. Reuteri) in Healthy Adults

NCT00922727
View directory record Official record
Conditions
Colic, Gastrointestinal Tract Infections
Interventions
L. reuteri, Sunflower Oil
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Jun 26, 2026, 9:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects

NCT01768663
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Lumacaftor, Ivacaftor, Ciprofloxacin, Itraconazole, Rifampin
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Jun 26, 2026, 9:25 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children

NCT01545375
View directory record Official record
Conditions
Infections, Streptococcal
Interventions
Pneumococcal vaccine GSK2189242A, Placebo, Prevnar 13®, PedvaxHIB®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
1,806 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
5
States / cities
Chinle, Arizona • Fort Defiance, Arizona • Whiteriver, Arizona + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Jun 26, 2026, 9:25 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Chewing Capability Study for Infants and Toddlers

NCT02156986
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
Société des Produits Nestlé (SPN)
Industry
Eligibility
9 Months to 36 Months
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2014 · Synced Jun 26, 2026, 9:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Thermal Imaging in Neonates: A Feasibility Study in Healthy Babies and Babies With Suspected TTN

NCT02570828
View directory record Official record
Conditions
Thermal Imaging, Neonatal Pneumonia, Tachypnea
Interventions
Thermal Imaging
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Up to 3 Days
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 15, 2017 · Synced Jun 26, 2026, 9:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants

NCT05867147
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Vanzacaftor, Vanzacaftor Placebo, Moxifloxacin, Moxifloxacin Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Jun 26, 2026, 9:25 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks

NCT03954743
View directory record Official record
Conditions
Infections, Rotavirus
Interventions
PCV-free liquid formulation of GSK's oral live attenuated HRV vaccine, Lyophilized formulation of GSK's oral live attenuated HRV vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
1,351 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
19
States / cities
Birmingham, Alabama • Colorado Springs, Colorado • Louisville, Kentucky + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Jun 26, 2026, 9:25 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

NCT00289783
View directory record Official record
Conditions
Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions
GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine, ActHIB, PedvaxHIB, Pediarix, Prevnar, M-M-R II, Varivax
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 15 Months
Enrollment
4,441 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
88
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 76 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Jun 26, 2026, 9:25 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Real-Time Assessment of Lung Structure and Function in Children and Young Adults With CF Using Electrical Impedance Tomography

NCT05455671
View directory record Official record
Conditions
Cystic Fibrosis, Healthy
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
3 Years to 21 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Jun 26, 2026, 9:25 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Differences Between Breastfed and Formula Fed Infants

NCT03493711
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
2 Months to 3 Months
Enrollment
158 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Jun 26, 2026, 9:25 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects

NCT03669614
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Inhaled AR-501, Inhaled Placebo
Drug
Lead sponsor
Aridis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
25
States / cities
Tucson, Arizona • Long Beach, California • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Jun 26, 2026, 9:25 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Early Allergen System Experience

NCT06262867
View directory record Official record
Conditions
Food Allergy in Infants
Interventions
Ready. Set. Food! Stage 1 Mix ins
Dietary Supplement
Lead sponsor
Prollergy dba Ready Set Food
Other
Eligibility
2 Months to 5 Months
Enrollment
1,110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Jun 26, 2026, 9:25 AM EDT